贝伐珠单抗联合放疗治疗EGFR野生型肺腺癌脑转移的临床研究  

Clinical Research of Bevacizumab Combined with Radiation Therapy in EGFR Non-mutation Lung Adenocarcinoma with Brain Metastasis

作　　者：乔丽 许进荣 马德亮 张洪叶 李京烨 QIAO Li;XU Jinrong;MA Deliang;ZHANG Hongye;LI Jingye(Department of Medical Oncology,Linyi Central Hospital,Linyi 276400,China;Department of Cardiovascularology,Linyi Central Hospital,Shandong Province,Linyi 276400,China)

机构地区：[1]临沂市中心医院肿瘤内科,山东临沂276400 [2]临沂市中心医院心血管内科,山东临沂276400

出　　处：《中国医药指南》2023年第10期1-5,共5页Guide of China Medicine

基　　金：2021年度山东省医学会临床科研资金项目(齐鲁专项),项目编号:YXH2022ZX02040。

摘　　要：目的探究贝伐珠单抗联合放疗治疗表皮生长因子受体(EGFR)野生型肺腺癌脑转移的临床效果。方法于2020年5月至2022年5月采用随机数字表法将40例EGFR野生型肺腺癌脑转移患者分为参照组(全脑放疗+瘤区推量调强放疗)和试验组(贝伐珠单抗联合全脑放疗+瘤区推量调强放疗)各20例,对干预效果进行分析比较。结果与参照组20.00%相比,试验组50.00%治疗总有效率显著更高(P<0.05),治疗前研究对象的Karnofsky(KPS)评分、美国国立卫生研究院卒中量表(NIH Stroke Scale,NIHSS评分)、格拉斯哥昏迷计分(Glasgow Coma Scale,GCS)评分水平对比无显著差异(P>0.05),治疗后试验组KPS评分、GCS评分高于参照组,NIHSS评分低于参照组(P<0.05);在不良事件发生率上,参照组40.00%与试验组50.00%相比无显著差异(P>0.05);试验组无进展生存时间(PFS)、总生存期(OS)显著高于参照组(P<0.05)。结论将贝伐珠单抗联合放射治疗应用于EGFR野生型肺腺癌脑转移患者可显著提升疗效,改善精神状态、神经功能,提升生活质量,延长PFS、OS。Objective To discuss the clinical effects of bevacizumab combined with radiation therapy in epidermal growth factor receptor(EGFR)non-mutation lung adenocarcinoma with brain metastasis.Methods 40 EGFR non-mutation lung adenocarcinoma patients with brain metastasis treated from May 2020 to May 2022 in our hospital were selected and grouped by random number table.20 cases of taking the whole brain radiotherapy-boosting intensity-modulated radiation therapy for tumor area were set as reference group;20 cases of taking the bevacizumab and whole brain radiotherapy-boosting intensity-modulated radiation therapy for tumor area were set as test group.Intervention outcomes were probed.Results The total response rate in the test group(50.00%)was significantly higher than reference group(20.00%)(P<0.05);before therapy,there were no significant between-group differences about Karnofsky Performance Score(KPS),National Institute of Health Stroke Scale(NIHSS)and Glasgow Coma Scale(GCS)scores(P>0.05);after therapy,KPS and GCS scores in the test group were higher than reference group;NIHSS scores were lower than reference group(P<0.05);there were no significant differences about the toxic event rate in the reference group(40.00%)and test group(50.00%)(P>0.05);the progression-free survival(PFS)and overall survival(OS)in the test group were longer than reference group(P<0.05).Conclusion Bevacizumab combined with radiation therapy can greatly improve the therapy effects,mental states,neurological function and life quality,extend the PFS and OS for EGFR non-mutation lung adenocarcinoma patients with brain metastasis.

关 键 词：表皮生长因子受体 贝伐珠单抗 EGFR野生型肺腺癌 脑转移全脑放射治疗 神经功能 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]